FDA yet to confirm Sinopharm's EUA application for COVID-19 vaccine | Inquirer News

FDA yet to confirm Sinopharm’s EUA application for COVID-19 vaccine

/ 03:46 PM March 01, 2021

MANILA, Philippines — The Food and Drug Administration (FDA) has yet to confirm if China’s state-owned pharmaceutical company Sinopharm has indeed applied for an emergency use authorization (EUA) in the Philippines for its COVID-19 vaccine.

“As of Friday, there was no application. I’m not sure if they filed online,” FDA Director-General Eric Domingo said in a text message to INQUIRER.net when asked to confirm presidential spokesperson Harry Roque’s statement that Sinopharm has already applied for an EUA.

READ: Sinopharm seeks EUA for Covid-19 vaccine in PH

ADVERTISEMENT

Domingo said the FDA office is closed because of the observance of Muntinlupa Day.

FEATURED STORIES

Roque earlier said that President Rodrigo Duterte prefers to get the Covid-19 developed by Sinopharm.

The FDA earlier allowed the compassionate use of 10,000 doses of Sinopharm vaccines for members of the Presidential Security Group. This means that the vaccines can be administered to them even without an EUA.

So far, only Pfizer-BioNTech, AstraZeneca, and Sinovac Biotech have secured EUA from the Philippines’ FDA for their Covid-19 vaccines.

ac
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: coronavirus Philippines, COVID-19, COVID-19 Vaccine, Eric Domingo, Sinopharm

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.